Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eliglustat (Genz-112638) in Gaucher disease type 1
2008-005222-37Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Gaucher disease type 1 (GD1) comparing Eliglustat with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2009; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2008-005222-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005222-37.